CLINICAL TRIALS PROFILE FOR ZEPZELCA

All Clinical Trials for ZEPZELCA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05042934 ↗	Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma	Not yet recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2021-09-15	This phase Ib/II trial studies best dose and side effects of lurbinectedin and how well it works with or without irinotecan in treating patients with Ewing sarcoma that has come back (relapsed) or is high risk and has spread to other places in the body (metastatic). Lurbinectedin may decrease chemicals in the body related to Ewing sarcoma, and reducing these chemicals may make the tumor cells more sensitive to irinotecan. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving lurbinectedin with or without irinotecan may work better in treating patients with Ewing sarcoma.
NCT05042934 ↗	Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma	Not yet recruiting	M.D. Anderson Cancer Center	Phase 1/Phase 2	2021-09-15	This phase Ib/II trial studies best dose and side effects of lurbinectedin and how well it works with or without irinotecan in treating patients with Ewing sarcoma that has come back (relapsed) or is high risk and has spread to other places in the body (metastatic). Lurbinectedin may decrease chemicals in the body related to Ewing sarcoma, and reducing these chemicals may make the tumor cells more sensitive to irinotecan. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving lurbinectedin with or without irinotecan may work better in treating patients with Ewing sarcoma.
NCT05099666 ↗	Lurbinectedin + Doxorubicin In Leiomyosarcoma	Not yet recruiting	Jazz Pharmaceuticals	Phase 1/Phase 2	2022-03-01	This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with soft tissue sarcoma. The second part is a randomized study to determine which is more effective at treating leiomyosarcoma, lurbinectedin with doxorubicin or lurbinectedin alone.

Clinical Trial Conditions for ZEPZELCA

Condition Name

Condition Name for ZEPZELCA
Intervention	Trials
Metastatic Soft-tissue Sarcoma	1
Pancreas Cancer	1
Recurrent Ewing Sarcoma	1

Condition MeSH

Condition MeSH for ZEPZELCA
Intervention	Trials
Sarcoma	2
Pancreatic Neoplasms	1
Leiomyosarcoma	1

Clinical Trial Locations for ZEPZELCA

Trials by Country

Trials by Country for ZEPZELCA
Location	Trials
United States	4

Trials by US State

Trials by US State for ZEPZELCA
Location	Trials
Georgia	1
Arizona	1
Massachusetts	1
Texas	1

Clinical Trial Progress for ZEPZELCA

Clinical Trial Phase

Clinical Trial Phase for ZEPZELCA
Clinical Trial Phase	Trials
Phase 2	1
Phase 1/Phase 2	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for ZEPZELCA
Clinical Trial Phase	Trials
Not yet recruiting	4

Clinical Trial Sponsors for ZEPZELCA

Sponsor Name

Sponsor Name for ZEPZELCA
Sponsor	Trials
Jazz Pharmaceuticals	3
National Cancer Institute (NCI)	2
Emory University	1

Sponsor Type

Sponsor Type for ZEPZELCA
Sponsor	Trials
Other	4
Industry	3
NIH	2

ZEPZELCA (Lutetium Lu 177 oxodotreotide) Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 23, 2026

What is the current status of ZEPZELCA clinical trials?

ZEPZELCA (lutetium Lu 177 oxodotreotide), developed by Advanced Accelerator Applications, a Novartis company, is approved for neuroendocrine tumors (NETs). Its approval followed results from the NETTER-1 trial, which demonstrated significant efficacy in midgut NETs. The ongoing clinical development aims to broaden applications across somatostatin receptor-positive tumors.

Regulatory approvals and trial status

• FDA approval: March 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
• EMA approval: April 2018, aligned with FDA.
• Major ongoing trials:
  • NETTER-2 trial (Phase 3): Evaluates ZEPZELCA in NETs of the pancreas and midgut. Initiated in 2019, with primary completion expected by late 2023.
  • COMPETE trial (Phase 2): Investigates efficacy in bronchial NETs.
  • Additional studies: Examining combination therapy potential with other targeted agents.

Clinical trial outcomes

• NETTER-1 (2021 update): Median progression-free survival (PFS) of 14.3 months versus 6.7 months for octreotide in control.
• Safety profile: Mainly mild hematologic toxicity, manageable with supportive care.

How does ZEPZELCA perform in the current market?

Market size and segmentation

• Global neuroendocrine tumor market: Estimated at USD 1.2 billion in 2022; projected to grow at a CAGR of 8% through 2030.
• Key regions:
  • North America: 45% market share
  • Europe: 35%
  • Asia-Pacific: 15%
  • Rest of the World: 5%

Competition landscape

• Main competitors include:
  • Lutathera (lutetium Lu 177 dotatate): First-to-market radiopharmaceutical for NETs.
  • Somatostatin analogs (octreotide, lanreotide): For symptom control and tumor stabilization.
• Unlike Lutathera, ZEPZELCA's broader approval and ongoing trials target multiple tumor types and lines of therapy.

Adoption factors

• Payer coverage: Limited initial coverage, but expanding as clinical data supports broader indications.
• Physician adoption: Driven by positive trial outcomes and ease of use in specialized centers.
• Pricing: Approximately USD 35,000 per treatment cycle; high cost influences payer policies.

What are the future market projections?

Revenue forecasts

Year	Projected Sales (USD billions)	Assumptions
2023	0.2	Launch in select markets; initial adoption
2025	0.55	Expansion of indications; increased adoption
2030	1.2	Broader indications; global market penetration

Growth drivers

• Successful completion of ongoing Phase 3 trials.
• Expansion into new indications, including bronchial NETs.
• Increasing awareness and diagnostic testing for SSTR-positive tumors.
• Strategic partnerships to facilitate global distribution.

Challenges

• Competition from Lutathera, which possesses a first-mover advantage.
• Regulatory delays or rejections for new indications.
• Manufacturing capacity constraints for radiopharmaceutical production.

Key considerations for stakeholders

• Investors: Focus on trial outcomes and potential expansion pathways.
• Manufacturers: Scale production capacity aligned with projected demand.
• Clinicians: Stay updated on trial results and emerging indications for expanded use.

Key Takeaways

• ZEPZELCA is approved for GEP-NETs with ongoing trials targeting broader indications.
• The market size for radioligand therapy in NETs is expected to double between 2022-2030.
• Competition remains stiff with Lutathera holding first-mover advantage; however, ZEPZELCA's broader trial pipeline offers growth potential.
• Regulatory success and trial outcomes will be critical to market penetration and revenue growth in coming years.

FAQs

1. Will ZEPZELCA be effective for other tumor types?
Ongoing clinical trials are assessing efficacy in bronchial and pancreatic NETs, with potential expansion to other somatostatin receptor-positive cancers.

2. When might ZEPZELCA receive additional regulatory approvals?
If ongoing Phase 3 trials demonstrate positive results, filings for additional indications could occur by 2024-2025.

3. How does the safety profile compare to Lutathera?
Both radioligand therapies share similar hematologic toxicity profiles. ZEPZELCA has shown manageable side effects in trials, comparable to Lutathera.

4. What are the main barriers to market growth?
Limited initial coverage, competition from Lutathera, and manufacturing capacity are primary hurdles.

5. What is the estimated timeline for market expansion?
Broad adoption could occur after positive Phase 3 trial results, with some expansion already underway in 2023.

---

References

[1] Netter-1 trial. (2021). "Efficacy and Safety of Lutetium Lu 177 Oxodotreotide in Neuroendocrine Tumors." Journal of Clinical Oncology.
[2] MarketsandMarkets. (2022). "Neuroendocrine Tumor Therapeutics Market."
[3] Novartis. (2018). "ZEPZELCA (Lutetium Lu 177 Oxodotreotide) Approval."
[4] Evaluate Pharma. (2022). "Radiopharmaceuticals Market Forecasts."